Gluconat De Calciu Zentiva

Gluconat De Calciu Zentiva is an intravenous solution that contains calcium gluconate monohydrate as its active ingredient. It is supplied in a sterile liquid form for parenteral administration and is marketed in the European Union. The product is classified as a calcium supplement and is prescribed to correct calcium deficiency and related electrolyte disturbances. It is available by prescription and should be administered by healthcare professionals under monitoring.

Gluconat De Calciu Zentiva is used when rapid correction of low calcium levels is required. The intravenous formulation allows direct delivery of calcium ions into the bloodstream.

- Treatment of documented hypocalcemia in acute care settings - Management of calcium deficiency associated with malnutrition or chronic disease - Adjunct therapy during cardiac arrest caused by severe hyperkalemia - Component of parenteral nutrition regimens to meet calcium requirements - Electrolyte replacement during major surgery or extensive blood loss

Adverse reactions to calcium gluconate intravenous infusion are generally infrequent, but they can be categorized by frequency and severity.

Common: - Mild irritation or pain at the infusion site - Transient flushing or warmth sensation - Nausea or mild gastrointestinal discomfort - Light‑headedness or mild hypotension - Headache or mild muscle cramps

Serious: - Severe hypercalcemia leading to cardiac arrhythmia - Anaphylactic or severe allergic reaction - Tissue necrosis from extravasation of the solution - Marked hypotension requiring intervention - Severe bronchospasm or respiratory distress

Before using Gluconat De Calciu Zentiva, clinicians should evaluate patient‑specific factors and monitor relevant parameters.

- Verify baseline serum calcium and adjust dose accordingly - Reduce infusion rate in patients with renal impairment - Monitor cardiac rhythm and blood pressure during administration - Ensure proper intravenous line placement to avoid extravasation - Use caution in patients with existing hypercalcemia or hyperparathyroidism - Review pregnancy and lactation status; safety data are limited - Discontinue infusion if signs of severe adverse reaction appear

Calcium gluconate may interact with several medications, affecting their absorption, distribution, or cardiac effects.

Avoid: - Digoxin, because calcium can increase its toxicity - Calcium channel blockers, which may have additive cardiovascular effects - Loop diuretics, which can alter calcium balance and increase loss - Tetracycline or fluoroquinolone antibiotics, whose absorption is reduced by calcium

Use with caution: - Beta‑blockers, due to potential enhanced hypotensive effect - ACE inhibitors or ARBs, which may affect renal calcium handling - Warfarin, as calcium may influence INR stability - Magnesium sulfate, because combined use can potentiate neuromuscular blockade - Phosphate binders, which may bind calcium and reduce its availability